BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qin Q, Li X, Liang X, Zeng L, Wang J, Sun L, Zhong D. Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer. Thorac Cancer 2021;12:1708-15. [PMID: 33943009 DOI: 10.1111/1759-7714.13906] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Qin Q, Li X, Liang X, Zeng L, Wang J, Sun L, Zhong D. Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer. Thorac Cancer 2021;12:1708-15. [PMID: 33943009 DOI: 10.1111/1759-7714.13906] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Gu Z, Shi C, Li J, Han Y, Sun B, Zhang W, Wu J, Zhou G, Ye W, Li J, Zhang Z, Zhou R. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma. BMC Med 2022;20:175. [PMID: 35546399 DOI: 10.1186/s12916-022-02373-6] [Reference Citation Analysis]
3 Ríos-Hoyo A, Moliner L, Arriola E. Acquired Mechanisms of Resistance to Osimertinib-The Next Challenge. Cancers (Basel) 2022;14:1931. [PMID: 35454838 DOI: 10.3390/cancers14081931] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bertoli E, De Carlo E, Del Conte A, Stanzione B, Revelant A, Fassetta K, Spina M, Bearz A. Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It? IJMS 2022;23:6936. [DOI: 10.3390/ijms23136936] [Reference Citation Analysis]
5 Peindl M, Göttlich C, Crouch S, Hoff N, Lüttgens T, Schmitt F, Pereira JGN, May C, Schliermann A, Kronenthaler C, Cheufou D, Reu-Hofer S, Rosenwald A, Weigl E, Walles T, Schüler J, Dandekar T, Nietzer S, Dandekar G. EMT, Stemness, and Drug Resistance in Biological Context: A 3D Tumor Tissue/In Silico Platform for Analysis of Combinatorial Treatment in NSCLC with Aggressive KRAS-Biomarker Signatures. Cancers (Basel) 2022;14:2176. [PMID: 35565305 DOI: 10.3390/cancers14092176] [Reference Citation Analysis]